Metformin SLC22A1 Reduced Efficacy Probability

Assess metformin hepatic uptake and glucose-lowering efficacy from SLC22A1 (OCT1) loss-of-function variant status.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Assess metformin hepatic uptake and glucose-lowering efficacy from SLC22A1 (OCT1) loss-of-function variant status

Each component has a specific meaning:

  • SLC22A1 loss-of-function variant status — The slc22a1 loss-of-function variant status recorded for the scenario being assessed.

Note: Interpret the metformin slc22a1 result against the thresholds and context described above.

How to Use

Enter the SLC22A1 loss-of-function variant status for the scenario you are assessing. Assess metformin hepatic uptake and glucose-lowering efficacy from SLC22A1 (OCT1) loss-of-function variant status. Use the metformin slc22a1 result to inform your calculation.

Related Calculators

Metformin eGFR Dose

Medical Ultra-depth

Frequently Asked Questions